Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a 12-week, multicenter, open-label extension study to evaluate the safety and
efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD
or related condition. Patients recruited into this trial are those who have successfully
completed the double-blind study, TNX-CY-P201 (AtEase Study). Patients will not be made aware
of the therapy they received during the double-blind study.